ProImmune has introduced B cell ELISpot assay as a service for the characterization of adaptive immune responses to infection, immune modulators, vaccines and therapeutic agents.
B cell ELISpot enables the activity of antibody-secreting memory B cells to be characterized at a cellular level.
The characterization gives a detailed reading of immune responses in contrast to an ELISA-type assay, which measures total levels of secreted antibodies in a sample.
ProImmune CEO Nikolai Schwabe said the B cell ELISpot is a valuable assay offering a superior method for characterisation of memory antibody responses, the investigation of which forms a mainstay of evaluating functional immune responses.
"Although the assay is technically challenging, requiring extensive experience, when performed correctly it is very robust and is therefore very well suited to be run as a core facility service," Schwabe added.
